Clinical Trial: NCT05061550
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Drug: Durvalumab
- Drug: Oleclumab
- Drug: Monalizumab
- Drug: Dato-DXd
- Drug: AZD0171
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed/Cisplatin
- Drug: Pemetrexed/Carboplatin
- Drug: Carboplatin/Paclitaxel
- Drug: Volrustomig
- Drug: Rilvegostomig
Other Study ID Numbers
- D9077C00001
- 2023-508852-21-00
- 2021-003369-37
- 2023
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Official Title
Conditions
Intervention / Treatment
- Drug: Durvalumab
- Drug: Oleclumab
- Drug: Monalizumab
- Drug: Dato-DXd
- Drug: AZD0171
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed/Cisplatin
- Drug: Pemetrexed/Carboplatin
- Drug: Carboplatin/Paclitaxel
- Drug: Volrustomig
- Drug: Rilvegostomig
Other Study ID Numbers
- D9077C00001
- 2023-508852-21-00
- 2021-003369-37
- 2023